ClinicalTrials.gg
CompletedNCT01958918SALTUpdated Mar 21, 2019Results posted

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

A Phase 4 interventional study of Ranibizumab and Aflibercept in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 68 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
712
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
8th of 124
712 · median 64
Started
2013
with 8 others
Phase 4
33 of 125
none open now
Registered
80th of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 8th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 33 in phase 4, and was the 80th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.

Read the detailed description

Patients attended 14 scheduled study visits during 12 months.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • wet age-related macular degeneration (AMD)
  • ranibizumab
  • aflibercept
  • Best Corrected Visual Acuity (BCVA)
  • Spectral Domain Optical Coherence Tomography (SD-OCT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Visual impairment predominantly due to neovascular AMD Active
  • Newly diagnosed, untreated, angiographically documented choroidal neovascularization (CNV) lesion

Key Exclusion Criteria:

  • Stroke or myocardial infarction less than 3 Months prior to study entry
  • Active injection or inflammation of either eye at the time of study entry
  • Any type of systemic disease (or received treatment for it), including any medical condition (controlled or uncontrolled) that were to be expected to progress, recur, or change to an extent which could bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
712 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity

    Drug: Ranibizumab

  • Active comparator
    Aflibercept

    1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months

    Drug: Aflibercept

Interventions

  • 0.5 mg intravitreal injection

    Also known as: Lucentis®

  • 2 mg intravitreal injection

    Also known as: Eylea®

06

What researchers measure

Primary outcomes

  1. Mean of the Absolute Values of CSRT Difference Month 3 to Month 6

    The thickness of the retina was measured by Spectral Domain Optical Coherence Topography (SD-OCT). The mean of the absolute values of the CSRT difference between Month 3 and 4, Month 4 and 5, and Month 5 and 6 was calculated (ie, CSRT fluctuation). A lower average CSRT fluctuation demonstrates greater retinal stability. One eye (study eye) contributed to the analysis.

    Time frame: Month 3, Month 4, Month 5, Month 6

Secondary outcomes

  1. Total Best Corrected Visual Acuity (BCVA) Score Measured in ETDRS Letters at Month 12

    Visual acuity was assessed in a sitting position with refraction using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. A higher score indicates better visual acuity. ETDRS scale ranges from 0-100 letters. A score of 65 to 70 letters represents a low to moderate visual acuity

    Time frame: Month 12

  2. IREST at Month 12

    Number of incorrectly read words (IREST) was assessed using International Reading Speed Texts (IResT) and measured in words per minute.

    Time frame: Month 12

  3. National Eye Institute Visual Functioning Questionnaire Composite Score (VFQ-25) at Month 12

    Vision-related quality of life was assessed by the patient using the National Eye Institute Visual Function Questionnaire. The scores of 12 subscales (general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision) were added together for a total (composite) score, which ranged from 0 to 100. A higher score indicates poorer function.

    Time frame: Month 12

  4. Correlations Between CSRT Fluctuation (Month 3 to 6) and Functional Outcomes at Month 12 (Full Analysis Set)

    Correlation coefficient calculated based on Pearson's correlation between each corresponding parameter and CSRT stability.

    Time frame: Month 3 to Month 6, Month 12

07

Results

Posted Mar 21, 2019

Participant flow

Patients were recruited from 6 sites in Austria, 2 sites in Belgium, 2 sites in Denmark and 5 sites from France.

Participant flow — Overall Study
MilestoneRanibizumabAflibercept
Started356356
Full analysis set353354
Completed313314
Not completed4342
Withdrew: Death13
Withdrew: Lost to follow-up47
Withdrew: Withdrawal by subject138
Withdrew: Lack of efficacy1310
Withdrew: Adverse event1212
Withdrew: Administrative problems02

Outcome measures

PrimaryMean of the Absolute Values of CSRT Difference Month 3 to Month 6

The thickness of the retina was measured by Spectral Domain Optical Coherence Topography (SD-OCT). The mean of the absolute values of the CSRT difference between Month 3 and 4, Month 4 and 5, and Month 5 and 6 was calculated (ie, CSRT fluctuation). A lower average CSRT fluctuation demonstrates greater retinal stability. One eye (study eye) contributed to the analysis.

Time frame:
Month 3, Month 4, Month 5, Month 6
Reported as:
Mean · micrometers
Mean of the Absolute Values of CSRT Difference Month 3 to Month 6
micrometersRanibizumabAflibercept
Mean of the Absolute Values of CSRT Difference Month 3 to Month 625.16 ± 2.58429.28 ± 2.620
Statistical analysis
  • Ranibizumab vs Aflibercept · ANOVA · p = 0.1850
SecondaryTotal Best Corrected Visual Acuity (BCVA) Score Measured in ETDRS Letters at Month 12

Visual acuity was assessed in a sitting position with refraction using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. A higher score indicates better visual acuity. ETDRS scale ranges from 0-100 letters. A score of 65 to 70 letters represents a low to moderate visual acuity

Time frame:
Month 12
Reported as:
Mean · letters
Total Best Corrected Visual Acuity (BCVA) Score Measured in ETDRS Letters at Month 12
lettersRanibizumabAflibercept
Total Best Corrected Visual Acuity (BCVA) Score Measured in ETDRS Letters at Month 1266.4 ± 18.1068 ± 17.62
SecondaryIREST at Month 12

Number of incorrectly read words (IREST) was assessed using International Reading Speed Texts (IResT) and measured in words per minute.

Time frame:
Month 12
Reported as:
Mean · incorrect words per minute
IREST at Month 12
incorrect words per minuteRanibizumabAflibercept
IREST at Month 125.7 ± 21.196.1 ± 21.86
SecondaryNational Eye Institute Visual Functioning Questionnaire Composite Score (VFQ-25) at Month 12

Vision-related quality of life was assessed by the patient using the National Eye Institute Visual Function Questionnaire. The scores of 12 subscales (general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision) were added together for a total (composite) score, which ranged from 0 to 100. A higher score indicates poorer function.

Time frame:
Month 12
Reported as:
Mean · units on a scale
National Eye Institute Visual Functioning Questionnaire Composite Score (VFQ-25) at Month 12
units on a scaleRanibizumabAflibercept
National Eye Institute Visual Functioning Questionnaire Composite Score (VFQ-25) at Month 1280.0 ± 14.4379.1 ± 14.95
SecondaryCorrelations Between CSRT Fluctuation (Month 3 to 6) and Functional Outcomes at Month 12 (Full Analysis Set)

Correlation coefficient calculated based on Pearson's correlation between each corresponding parameter and CSRT stability.

Time frame:
Month 3 to Month 6, Month 12
Reported as:
Number · correlation coefficient
Correlations Between CSRT Fluctuation (Month 3 to 6) and Functional Outcomes at Month 12 (Full Analysis Set)
correlation coefficientRanibizumabAflibercept
Total BCVA Score-0.21940.0155
IREST reading speed (words/minute)0.08890.0450
VFQ-25 composite score0.10640.0847

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg1/356 (0.3%)67/356 (18.8%)156/356 (43.8%)
Aflibercept 2 mg3/356 (0.8%)74/356 (20.8%)156/356 (43.8%)
Most frequent serious events
Showing 10 of 178
Most frequent serious events
EventRanibizumab 0.5 mgAflibercept 2 mg
Angina pectorisCardiac disorders1/3565/356
Coronary artery diseaseCardiac disorders3/3564/356
PneumoniaInfections and infestations1/3564/356
OsteoarthritisMusculoskeletal and connective tissue disorders4/3561/356
Hypertensive crisisVascular disorders4/3561/356
ConstipationGastrointestinal disorders0/3563/356
ContusionInjury, poisoning and procedural complications1/3563/356
Rib fractureInjury, poisoning and procedural complications1/3563/356
DehydrationMetabolism and nutrition disorders0/3563/356
Back painMusculoskeletal and connective tissue disorders1/3563/356
Most frequent other events
Most frequent other events
EventRanibizumab 0.5 mgAflibercept 2 mg
Viral upper respiratory tract infectionInfections and infestations43/35662/356
Conjunctival haemorrhageEye disorders41/35628/356
Intraocular pressure increasedInvestigations29/35623/356
Visual acuity reducedEye disorders19/35625/356
Eye painEye disorders24/35623/356
InfluenzaInfections and infestations22/35612/356
Back painMusculoskeletal and connective tissue disorders12/35621/356
HypertensionVascular disorders16/35621/356
Ocular hyperaemiaEye disorders20/3569/356
Dry eyeEye disorders18/35611/356

Baseline characteristics

FAS

Age, Continuous
Age, Continuous(years)RanibizumabAfliberceptTotal
Mean77.3 ± 7.5378.0 ± 7.2177.7 ± 7.38
Sex: Female, Male
Sex: Female, Male(Participants)RanibizumabAfliberceptTotal
Female210218428
Male143136279
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RanibizumabAfliberceptTotal
Caucasian350352702
Asian101
Other224
08

Study locations

68 sites
  • Novartis Investigative Site
    Feldkirch, A-6807, Austria
  • Novartis Investigative Site
    Graz, A-8036, Austria
  • Novartis Investigative Site
    Linz, A-4020, Austria
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Vienna, A-1130, Austria
  • Novartis Investigative Site
    Laeken, 1020, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Glostrup, 2600, Denmark
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    Creteil, 94000, France
  • Novartis Investigative Site
    Dijon, 21034, France
  • Novartis Investigative Site
    Paris cedex 10, 75010, France
  • Novartis Investigative Site
    Paris, Cedex 12, F-75571, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
  • Novartis Investigative Site
    Bad Rothenfelde, 49214, Germany
  • Novartis Investigative Site
    Bayreuth, 95444, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 12203, Germany
  • Novartis Investigative Site
    Bonn, 53127, Germany
  • Novartis Investigative Site
    Bremen, 28213, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Darmstadt, 64297, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Glauchau, 08371, Germany
  • Novartis Investigative Site
    Gottingen, 37075, Germany
  • Novartis Investigative Site
    Hagen, 58097, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Homburg, 66421, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50924, Germany
  • Novartis Investigative Site
    Koeln, 50935, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Marburg, 35039, Germany
  • Novartis Investigative Site
    Muelheim, 45468, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Siegburg, 53721, Germany
  • Novartis Investigative Site
    Sulzbach, 66280, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Ulm, 89075, Germany
  • Novartis Investigative Site
    Wolfsburg, 38442, Germany
  • Novartis Investigative Site
    Wurzburg, 97080, Germany
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Den Bosch, 5223 GZ, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6500 HB, Netherlands
  • Novartis Investigative Site
    Arendal, 4800, Norway
  • Novartis Investigative Site
    Oslo, 0264, Norway
  • Novartis Investigative Site
    Braga, 4710243, Portugal
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Coimbra, 3030-163, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-078, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-085, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Porto, 4200 319, Portugal
  • Novartis Investigative Site
    Vila Franca de Xira, 2600-009, Portugal
  • Novartis Investigative Site
    Vila Nova de Gaia, 4434 502, Portugal
  • Novartis Investigative Site
    Stockholm, 112 82, Sweden
  • Novartis Investigative Site
    Vasteras, 72189, Sweden
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Fribourg, 1708, Switzerland
  • Novartis Investigative Site
    Genève, 1204, Switzerland
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Nov 2016, 36 months.

Results were first posted in Mar 2019, 2 years 3 months after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 36 months is above that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2013
First posted
Oct 9, 2013
StartActual
Oct 23, 2013
Primary completionActual
Nov 22, 2016
CompletionActual
May 29, 2017
Results first posted
Mar 21, 2019
Last update
Mar 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01958918
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Oct 23, 2013
Primary completion
Nov 22, 2016
Completion
May 29, 2017
Results posted
Mar 21, 2019
Last update
Mar 21, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion